TNFRSF17 and graft versus host disease: It is slao essential to examine the safety and in vivo persistence of universal CAR-T cells through clinical trials.446,456–460 Anti-CD19 universal CAR-T cells, like PBCAR0191 and bispecific universal CAR-T CTA101, also showed high rates of CR (60% and 83.3%).301,461 81.8% of patients showed OR after RD13-01 infusion (CRR 63.6%) without GVHD and severe CRS.458 A phase 1 UNIVERSAL trial reported a first-in-class, allogeneic, anti-BCMA CAR-T cell therapy (ALLO-715) engineered to abrogate GVHD and minimize CAR-T rejection.